{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:19:58Z","timestamp":1792793998082,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and Aims:<\/jats:title>\n            <jats:p>Observational studies have shown an association between statin or aspirin use and a decreased risk of HCC, but the effects of a well-defined treatment strategy remain unknown. We emulated trials of the effects of continuous statin or aspirin use on HCC risk in patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results:<\/jats:title>\n            <jats:p>We specified target trials for statins and, separately, aspirin and emulated them using Danish health care registries. All eligible patients with ALD cirrhosis diagnosed in 2000\u20132018 were included in either an exposed or an unexposed arm. Patients were followed until HCC or death without HCC. The 5-year risk of HCC was estimated using marginal structural models with inverse probability weighting. Using statins continuously for 5 years compared with not using statins resulted in a relative risk (RR) of HCC of 0.67 (95% CI: 0.45\u20130.91). The RR of death without HCC was 0.69 (95% CI: 0.65\u20130.77). For aspirin, the RR was 1.05 (95% CI: 0.60\u20131.42) for HCC and 1.02 (95% CI: 0.95\u20131.09) for death without HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In patients with ALD cirrhosis, 5 years of continuous statin use resulted in a 33% RR reduction of HCC (number needed to treat = 94) and a 31% RR reduction of death without HCC (number needed to treat = 7). Such strong causal effects are implausible and best explained by uncontrollable confounding, highlighting the need for randomized trials. Aspirin use likely does not affect the risk of HCC or death without HCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hc9.0000000000000013","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:39:17Z","timestamp":1674578357000},"page":"e0013-e0013","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-6980","authenticated-orcid":false,"given":"Frederik","family":"Kraglund","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-5651","authenticated-orcid":false,"given":"Diana H.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-8359","authenticated-orcid":false,"given":"Andreas H.","family":"Eiset","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"Department of Affective Disorders, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-929X","authenticated-orcid":false,"given":"Gerda E.","family":"Villadsen","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-9356","authenticated-orcid":false,"given":"Joe","family":"West","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"},{"name":"NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-1430","authenticated-orcid":false,"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1]]},"reference":[{"key":"R1-20241015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/hep4.1564","article-title":"Hepatocellular carcinoma survival by etiology: a SEER-Medicare Database analysis","volume":"4","author":"Brar","year":"2020","journal-title":"Hepatol Commun"},{"key":"R2-20241015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MCG.0000000000001478","article-title":"Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients: a systematic review and meta-analysis","volume":"55","author":"Wong","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"R3-20241015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep4.1640","article-title":"Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"5","author":"Memel","year":"2021","journal-title":"Hepatol Commun"},{"key":"R4-20241015","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/ijc.32426","article-title":"Statin use and risk of liver cancer: evidence from two population-based studies","volume":"146","author":"Tran","year":"2020","journal-title":"Int J Cancer"},{"key":"R5-20241015","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/liv.15011","article-title":"Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: a nationwide population\u2010based study","volume":"41","author":"Choi","year":"2021","journal-title":"Liver Int"},{"key":"R6-20241015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MCG.0000000000001546","article-title":"Combined use of aspirin and statin is associated with a decreased incidence of hepatocellular carcinoma","volume":"56","author":"Singh","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"R7-20241015","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","article-title":"Association of aspirin with hepatocellular carcinoma and liver-related mortality","volume":"382","author":"Simon","year":"2020","journal-title":"N Engl J Med"},{"key":"R8-20241015","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/cancers14030825","article-title":"Statins reduce hepatocellular carcinoma risk in patients with chronic kidney disease and end-stage renal disease: a 17-year longitudinal study","volume":"14","author":"Sung","year":"2022","journal-title":"Cancers"},{"key":"R9-20241015","doi-asserted-by":"crossref","first-page":"e00324","DOI":"10.14309\/ctg.0000000000000324","article-title":"Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog","volume":"12","author":"Hui","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"R10-20241015","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20241015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"R12-20241015","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer","volume":"25","author":"Dickerman","year":"2019","journal-title":"Nat Med"},{"key":"R13-20241015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"key":"R14-20241015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish Cancer Registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"R15-20241015","first-page":"798","article-title":"Data Resource Profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R16-20241015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish Register of causes of death","volume":"39","author":"Helweg-Larsen","year":"2011","journal-title":"Scand J Public Health"},{"key":"R17-20241015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"R18-20241015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2020.05.043","article-title":"Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis","volume":"73","author":"Jepsen","year":"2020","journal-title":"J Hepatol"},{"key":"R19-20241015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1214\/12-AOS1058","article-title":"On the definition of a confounder","volume":"41","author":"VanderWeele","year":"2013","journal-title":"Ann Stat"},{"key":"R20-20241015","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"R21-20241015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R22-20241015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/1536867X0400400403","article-title":"Controlling for time-dependent confounding using marginal structural models","volume":"4","author":"Fewell","year":"2004","journal-title":"Stata J"},{"key":"R23-20241015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"R24-20241015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R25-20241015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"R26-20241015","doi-asserted-by":"crossref","first-page":"e011306","DOI":"10.1136\/bmjopen-2016-011306","article-title":"Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence","volume":"6","author":"Lavikainen","year":"2016","journal-title":"BMJ Open"},{"key":"R27-20241015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R28-20241015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1022835207287","article-title":"Data quality of administratively collected hospital discharge data for liver cirrhosis epidemiology","volume":"21","author":"Vestberg","year":"1997","journal-title":"J Med Syst"},{"key":"R29-20241015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson Comorbidity Index conditions in the population-based Danish National Registry of patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"R30-20241015","first-page":"535","article-title":"The Danish Cancer Registry\u2014history, content, quality and use","volume":"44","author":"Storm","year":"1997","journal-title":"Dan Med Bull"},{"key":"R31-20241015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/pds.4700","article-title":"Validating registry data on statins prescriptions by blood measurements","volume":"28","author":"Riis","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R32-20241015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/CLEP.S311450","article-title":"The validity of Danish prescription data to measure use of aspirin and other non-steroidal anti-inflammatory drugs and quantification of bias due to non-prescription drug use","volume":"13","author":"Gaster","year":"2021","journal-title":"Clin Epidemiol"},{"key":"R33-20241015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.annepidem.2015.10.007","article-title":"Unmeasured confounding in pharmacoepidemiology","volume":"26","author":"Groenwold","year":"2016","journal-title":"Ann Epidemiol"},{"key":"R34-20241015","doi-asserted-by":"crossref","first-page":"e48095","DOI":"10.1371\/journal.pone.0048095","article-title":"Statins and hip fracture prevention\u2014a population based cohort study in women","volume":"7","author":"Helin-Salmivaara","year":"2012","journal-title":"PLoS One"},{"key":"R35-20241015","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jamda.2019.06.027","article-title":"Effects of statins on relative risk of fractures for older adults: an updated systematic review with meta-analysis","volume":"20","author":"Shi","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"R36-20241015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R37-20241015","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-20241015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R39-20241015","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"R40-20241015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"R41-20241015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0039-1679956","article-title":"Prevention of hepatocellular carcinoma by statins: clinical evidence and plausible mechanisms","volume":"39","author":"Kim","year":"2019","journal-title":"Semin Liver Dis"},{"key":"R42-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:20:10Z","timestamp":1729030810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HC9.0000000000000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/hc9.0000000000000013","relation":{},"ISSN":["2471-254X"],"issn-type":[{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-09-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}